Li Zhou
Incyte
16 Papers
33 Citations
Li Zhou is an academic researcher from Incyte. The author has contributed to research in topics: Medicine & Tumor microenvironment. The author has an hindex of 7, co-authored 16 publications.
Chat about Author
Papers
Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
Raymond P. Perez,Matthew J. Riese,Karl D. Lewis,Mansoor N. Saleh,Adil Daud,Jordan Berlin,James J. Lee,Sutapa Mukhopadhyay,Li Zhou,Gul Serbest,Omid Hamid +10 more
TL;DR: Preliminary P1/2 safety and tolerability outcomes for the overall study population and P2 response for select tumor types are reported and preliminary DCR (CR+PR+SD) is presented.
95
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Andres Forero-Torres,Radhakrishnan Ramchandren,Abdulraheem Yacoub,Michael S. Wertheim,William Jeffery Edenfield,Paolo Caimi,Martin Gutierrez,Luke P. Akard,Carolina Escobar,Justin Call,Daniel O. Persky,Swaminathan P. Iyer,Douglas J DeMarini,Li Zhou,Xuejun Chen,Fitzroy Dawkins,Tycel Phillips +16 more
TL;DR: Parsaclisib has demonstrated antitumor activity in relapsed or refractory B-cell NHL with the potential for improved long-term patient outcomes and was registered at www.clinicaltrials.gov as #NCT02018861.
90
Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
Adil Daud,Mansoor N. Saleh,James C. Hu,Jonathan Bleeker,Matthew J. Riese,Roland Meier,Li Zhou,Gul Serbest,Karl D. Lewis +8 more
TL;DR: ECHO-204 is an open-label, phase (P) 1/2 study of E plus PD-1 inhibitor nivolumab in patients (pts) with advanced cancer in patients with advanced melanoma and results are reported on efficacy and safety/tolerability outcomes.
48
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel Phillips,Andres Forero-Torres,Taimur Sher,Catherine Diefenbach,Patrick B. Johnston,Moshe Talpaz,Jennifer Pulini,Li Zhou,Peggy Scherle,Xuejun Chen,Paul M. Barr +10 more
TL;DR: INCB040093 with/without itacitinib was tolerated and active in this study, and is a promising treatment strategy for patients with select R/R B-cell lymphomas.
48
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
Tycel Phillips,Andres Forero-Torres,Taimur Sher,Catherine Diefenbach,Moshe Talpaz,Peggy Scherle,Richard Schaub,Li Zhou,Jennifer Pulini,Lance Leopold,Matthew A. Spear,Paul M. Barr +11 more
TL;DR: This ongoing dose escalation study with expansion cohorts enrolled adult pts with r/r B-cell malignancies and found the most common AEs were fatigue, headache, and fatigue-like symptoms, which are similar to those seen in other inhibitors of PI3K or JAK-STAT.
9